From the Journals
TNFI-induced psoriasis improved or resolved with topical medications alone in 63.5% of patients.
Few left long-term extension study because of adverse events or loss of efficacy.
The highest coronary heart disease risks linked to inflammation are seen in SLE and systemic sclerosis, conditions that aren’t included in...
Those taking corticosteroids or other immunosuppressants are at particularly high risk, a systematic review of literature finds.
Efficacy was comparable with potent topical corticosteroids, but without the side-effects baggage.
Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis in Pediatric Patients
In November 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released their recommendations regarding...
Several agents are approved by the US Food and Drug Administration for pediatric psoriasis, and dupilumab is approved for pediatric atopic...
Preliminary evidence suggests biologics prevent the fearsome COVID-19 late cytokine storm.
If approved, mirikizumab, which binds the p19 subunit of IL-23, would join three other IL-23 drugs already marketed in the United States for...
“By mode of action, we think delgocitinib is more selective in the way of acting.”
For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or...